Pill Identifier App

Kepivance Amgen Inc. - Treatment for Severe Oral Mucositis in Cancer Patients

Kepivance is a recombinant human keratinocyte growth factor indicated to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients with hematologic (blood) cancers undergoing high-dose chemotherapy, with or without radiation, followed by a bone marrow transplant.

Posted: December 2004

Related Articles:

Kepivance (palifermin) FDA Approval History

View comments

Hide
(web1)